Browsing by Author "Saito, Naoyuki G."

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report
    (Elsevier, 2017-09-05) Cerra-Franco, Alberto; Grethlein, Sara J.; Bertrand, Todd E.; Wooden, William A.; Saito, Naoyuki G.; Radiation Oncology, School of Medicine
  • Thumbnail Image
    Item
    An Intracranial Hemorrhage Wrapped in an Enigma
    (Elsevier, 2019-10) McClelland, Shearwood, III; Saito, Naoyuki G.; Radiation Oncology, School of Medicine
    An 88-year-old man with Alzheimer's dementia who previously received a diagnosis of solitary Fuhrman grade 2 renal cell carcinoma1 managed with active surveillance presented to the emergency department for progressive left-sided headache and difficulty recognizing numbers and letters. He and his family denied history of trauma, fall, or anticoagulant use. This occurred 1 week after presenting to the same emergency department with a headache and being discharged home after negative head computed tomography, 2 months after spontaneous subarachnoid hemorrhage involving the right central sulcus, and 11 months after transient ischemic attack symptoms with negative workup.
  • Thumbnail Image
    Item
    Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer
    (Wolters Kluwer, 2024) Chen, Lujia; Wang, Ying; Cai, Chunhui; Ding, Ying; Kim, Rim S.; Lipchik, Corey; Gavin, Patrick G.; Yothers, Greg; Allegra, Carmen J.; Petrelli, Nicholas J.; Suga, Jennifer Marie; Hopkins, Judith O.; Saito, Naoyuki G.; Evans, Terry; Jujjavarapu, Srinivas; Wolmark, Norman; Lucas, Peter C.; Paik, Soonmyung; Sun, Min; Pogue-Geile, Katherine L.; Lu, Xinghua; Medicine, School of Medicine
    Purpose: A combination of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is the standard for adjuvant therapy of resected early-stage colon cancer (CC). Oxaliplatin leads to lasting and disabling neurotoxicity. Reserving the regimen for patients who benefit from oxaliplatin would maximize efficacy and minimize unnecessary adverse side effects. Methods: We trained a new machine learning model, referred to as the colon oxaliplatin signature (COLOXIS) model, for predicting response to oxaliplatin-containing regimens. We examined whether COLOXIS was predictive of oxaliplatin benefits in the CC adjuvant setting among 1,065 patients treated with 5-fluorouracil plus leucovorin (FULV; n = 421) or FULV + oxaliplatin (FOLFOX; n = 644) from NSABP C-07 and C-08 phase III trials. The COLOXIS model dichotomizes patients into COLOXIS+ (oxaliplatin responder) and COLOXIS- (nonresponder) groups. Eight-year recurrence-free survival was used to evaluate oxaliplatin benefits within each of the groups, and the predictive value of the COLOXIS model was assessed using the P value associated with the interaction term (int P) between the model prediction and the treatment effect. Results: Among 1,065 patients, 526 were predicted as COLOXIS+ and 539 as COLOXIS-. The COLOXIS+ prediction was associated with prognosis for FULV-treated patients (hazard ratio [HR], 1.52 [95% CI, 1.07 to 2.15]; P = .017). The model was predictive of oxaliplatin benefits: COLOXIS+ patients benefited from oxaliplatin (HR, 0.65 [95% CI, 0.48 to 0.89]; P = .0065; int P = .03), but COLOXIS- patients did not (COLOXIS- HR, 1.08 [95% CI, 0.77 to 1.52]; P = .65). Conclusion: The COLOXIS model is predictive of oxaliplatin benefits in the CC adjuvant setting. The results provide evidence supporting a change in CC adjuvant therapy: reserve oxaliplatin only for COLOXIS+ patients, but further investigation is warranted.
  • Thumbnail Image
    Item
    A Retrospective Analysis of 287 Patients Undergoing Prophylactic Radiation Therapy for the Prevention of Heterotopic Ossification
    (Elsevier, 2020-11-24) Freije, Samantha L.; Kushdilian, Michael V.; Burney, Heather N.; Zang, Yong; Saito, Naoyuki G.; Radiation Oncology, School of Medicine
    Purpose: Heterotopic ossification (HO) is a potentially disabling disorder of ectopic bone formation secondary to orthopedic surgery or trauma. In this retrospective analysis we evaluated the outcomes of patients who received radiation therapy (RT) for HO prophylaxis. Methods and materials: A total of 287 patients who received RT for HO prophylaxis at a major trauma center from 2007 to 2018 were analyzed. Data collected included types of injury, surgery, time intervals between key events, development of postprophylaxis HO, and secondary malignancies. Associations between various factors and the risk of developing HO were analyzed. Kaplan-Meier analysis was used to estimate failure rates. Results: The most common indication for RT was traumatic acetabular fracture (83.3%). Twelve patients (4.2%) developed postprophylaxis HO with a median time to failure of 8.6 months (2.8-24.5). Kaplan-Meier 1-, 2-, and 5-year failure rates were 3.7%, 4.4%, and 7.4%, respectively. Injury type and timing of RT were not associated with the risk of failure, but we observed a trend of increased risk of failure in patients with longer time between surgery and RT (odd ration [OR] 1.68, P = .056). Current or former smokers (51.7%) were less likely to fail (OR 0.10, P = .03). There was no incidence of in-field secondary malignancy. Conclusions: There was no significant association between injury and fracture type, surgical approach, or timing of RT and development of HO, contrary to published reports of increased HO risk with certain surgical approaches and longer time intervals between injury and surgery, suggesting that prophylactic RT might play a role in mitigating these effects. Decreased risk of postprophylaxis HO among former or current smokers was unexpected. No secondary malignancy in the RT field was identified, although the median follow-up was only 17 months. Compared with published HO incidences (17%-39%) in patients who receive no prophylaxis after traumatic acetabular fractures, our results are highly suggestive of the efficacy of prophylactic RT.